DAE HWA Pharmaceutical Statistics

Total Valuation

DAE HWA Pharmaceutical has a market cap or net worth of KRW 200.22 billion.

Market Cap	200.22B
Enterprise Value	n/a

Important Dates

The next estimated earnings date is Friday, February 7, 2025.

Earnings Date	Feb 7, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

DAE HWA Pharmaceutical has 17.52 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	17.52M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-15.40%
Owned by Insiders (%)	30.43%
Owned by Institutions (%)	2.14%
Float	12.19M

Valuation Ratios

The trailing PE ratio is 18.51.

PE Ratio	18.51
Forward PE	n/a
PS Ratio	1.73
PB Ratio	2.49
P/TBV Ratio	3.29
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.68, with a Debt / Equity ratio of 0.62.

Current Ratio	0.68
Quick Ratio	0.39
Debt / Equity	0.62
Debt / EBITDA	4.44
Debt / FCF	-3.84
Interest Coverage	1.20

Financial Efficiency

Return on equity (ROE) is 11.26% and return on invested capital (ROIC) is 2.64%.

Return on Equity (ROE)	11.26%
Return on Assets (ROA)	2.12%
Return on Capital (ROIC)	2.64%
Revenue Per Employee	374.37M
Profits Per Employee	34.94M
Employee Count	308
Asset Turnover	0.66
Inventory Turnover	3.99

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.15% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+20.15%
50-Day Moving Average	14,745.60
200-Day Moving Average	11,667.60
Relative Strength Index (RSI)	35.67
Average Volume (20 Days)	412,549

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DAE HWA Pharmaceutical had revenue of KRW 115.31 billion and earned 10.76 billion in profits. Earnings per share was 617.61.

Revenue	115.31B
Gross Profit	48.36B
Operating Income	5.94B
Pretax Income	14.67B
Net Income	10.76B
EBITDA	11.73B
EBIT	5.94B
Earnings Per Share (EPS)	617.61

Full Income Statement

Balance Sheet

The company has 9.83 billion in cash and 52.05 billion in debt, giving a net cash position of -42.22 billion or -2,410.05 per share.

Cash & Cash Equivalents	9.83B
Total Debt	52.05B
Net Cash	-42.22B
Net Cash Per Share	-2,410.05
Equity (Book Value)	83.28B
Book Value Per Share	4,591.03
Working Capital	-22.75B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.62 billion and capital expenditures -10.93 billion, giving a free cash flow of -13.55 billion.

Operating Cash Flow	-2.62B
Capital Expenditures	-10.93B
Free Cash Flow	-13.55B
FCF Per Share	-773.73

Full Cash Flow Statement

Margins

Gross margin is 41.94%, with operating and profit margins of 5.15% and 9.33%.

Gross Margin	41.94%
Operating Margin	5.15%
Pretax Margin	12.72%
Profit Margin	9.33%
EBITDA Margin	10.18%
EBIT Margin	5.15%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.31%.

Dividend Per Share	150.00
Dividend Yield	1.31%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	8.22%
Buyback Yield	-3.43%
Shareholder Yield	-2.11%
Earnings Yield	5.40%
FCF Yield	-6.77%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

DAE HWA Pharmaceutical has an Altman Z-Score of 2.84. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.84
Piotroski F-Score	n/a